JAZZ
Jazz Pharmaceuticals plc NASDAQ Listed Jun 1, 2007$224.66
-1.00%
vs $226.93
Mkt Cap $14.1B
52w Low $105.00
86.5% of range
52w High $243.32
50d MA $220.26
200d MA $175.05
P/E (TTM)
-38.5x
EV/EBITDA
143.7x
P/B
3.2x
Debt/Equity
1.3x
ROE
-8.2%
P/FCF
10.6x
RSI (14)
39.00
ATR (14)
$6.87
Beta
0.23
50d MA
$220.26
200d MA
$175.05
Avg Volume
933.6K
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
Waterloo Exchange · Dublin 4 · IE
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | AMC | 4.67 | 6.34 | +35.8% | 212.26 | +7.4% | +7.7% | -0.7% | -0.5% | -1.0% | +1.9% | — |
| Feb 24, 2026 | AMC | 6.52 | 6.64 | +1.8% | 173.83 | +3.5% | +13.2% | -4.0% | +0.6% | +0.2% | -2.0% | — |
| Nov 5, 2025 | AMC | 5.95 | 8.13 | +36.6% | 137.22 | +3.7% | -2.3% | -2.2% | +1.5% | +2.9% | -0.3% | — |
| Aug 5, 2025 | AMC | -6.12 | -8.25 | -34.8% | 113.20 | -5.0% | -6.4% | +5.8% | -0.7% | -0.5% | +2.3% | — |
| May 6, 2025 | AMC | 4.51 | 1.68 | -62.7% | 111.17 | -5.1% | -8.8% | -3.0% | -0.6% | +5.9% | -0.6% | — |
| Feb 25, 2025 | AMC | 5.83 | 6.60 | +13.2% | 139.67 | +0.6% | +3.2% | -0.6% | +0.2% | -2.3% | -0.9% | — |
| Nov 6, 2024 | AMC | 5.47 | 6.61 | +20.8% | 111.55 | +4.8% | +6.8% | +3.8% | +2.8% | +0.5% | -0.1% | — |
| Jul 31, 2024 | AMC | 4.68 | 5.30 | +13.2% | 110.25 | +2.6% | +3.7% | -1.0% | -1.5% | -0.2% | +0.8% | — |
| May 1, 2024 | AMC | 4.14 | 2.68 | -35.3% | 110.31 | -4.7% | -0.9% | +0.7% | -0.1% | +1.2% | -0.5% | — |
| Feb 28, 2024 | AMC | 5.26 | 5.02 | -4.6% | 129.70 | -3.2% | -8.3% | -0.0% | -1.1% | +0.8% | -1.0% | — |
| Nov 8, 2023 | AMC | 4.90 | 4.84 | -1.2% | 128.24 | +0.2% | -9.1% | +3.2% | +1.5% | +2.3% | +0.5% | — |
| Aug 9, 2023 | AMC | 4.46 | 4.51 | +1.1% | 133.00 | +4.3% | +1.6% | +3.1% | +0.5% | -0.0% | -1.4% | — |
| May 10, 2023 | AMC | 4.26 | 3.95 | -7.3% | 136.53 | +0.3% | +0.4% | -1.0% | -0.8% | -2.7% | +0.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 9 | Truist | Reiterates | Buy | $256 | $232.04 | $236.88 | +2.1% | -1.2% | +0.2% | +2.8% | -2.4% | +0.0% |
| May 22 | Bernstein | Initiates | Mkt Perform | $229 | $239.40 | $242.93 | +1.5% | +0.2% | -1.0% | +0.1% | -0.9% | +0.5% |
| May 19 | UBS | Upgrade | Neutral → Buy | $307 | $229.55 | $234.21 | +2.0% | +3.4% | +0.7% | +0.2% | +0.2% | -1.0% |
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $199.03 | $200.74 | +0.9% | +1.7% | -1.2% | -1.7% | +2.4% | +1.4% |
| Apr 20 | Barclays | Maintains | Overweight → Overweight | — | $203.42 | $206.34 | +1.4% | -0.4% | -1.7% | +1.7% | -1.2% | -1.7% |
| Mar 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $180.45 | $180.72 | +0.1% | +0.7% | -0.6% | +0.9% | +1.5% | +2.2% |
| Feb 25 | Morgan Stanley | Maintains | Overweight → Overweight | — | $173.83 | $180.00 | +3.5% | +13.2% | -4.0% | +0.6% | +0.2% | -2.0% |
| Feb 25 | BofA Securities | Maintains | Buy → Buy | — | $173.83 | $180.00 | +3.5% | +13.2% | -4.0% | +0.6% | +0.2% | -2.0% |
| Feb 25 | RBC Capital | Maintains | Outperform → Outperform | — | $173.83 | $180.00 | +3.5% | +13.2% | -4.0% | +0.6% | +0.2% | -2.0% |
| Feb 25 | Wells Fargo | Maintains | Overweight → Overweight | — | $173.83 | $180.00 | +3.5% | +13.2% | -4.0% | +0.6% | +0.2% | -2.0% |
| Jan 12 | Truist | Maintains | Buy → Buy | — | $161.13 | $162.63 | +0.9% | +1.6% | -0.8% | +5.2% | +0.2% | -1.0% |
| Jan 12 | Needham | Maintains | Buy → Buy | — | $161.13 | $162.63 | +0.9% | +1.6% | -0.8% | +5.2% | +0.2% | -1.0% |
| Dec 10 | Piper Sandler | Maintains | Overweight → Overweight | — | $162.26 | $165.35 | +1.9% | +1.7% | -0.0% | +1.6% | +1.2% | +0.1% |
| Nov 24 | UBS | Downgrade | Buy → Neutral | — | $176.93 | $174.89 | -1.2% | +2.2% | -0.5% | -1.7% | -0.2% | -2.5% |
| Nov 18 | Baird | Maintains | Outperform → Outperform | — | $170.09 | $170.09 | +0.0% | +6.1% | -2.5% | -0.2% | +0.7% | +2.2% |
| Nov 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $170.09 | $170.09 | +0.0% | +6.1% | -2.5% | -0.2% | +0.7% | +2.2% |
| Nov 18 | BofA Securities | Maintains | Buy → Buy | — | $170.09 | $170.09 | +0.0% | +6.1% | -2.5% | -0.2% | +0.7% | +2.2% |
| Nov 17 | Morgan Stanley | Maintains | Overweight → Overweight | — | $141.07 | $168.00 | +19.1% | +20.6% | +6.1% | -2.5% | -0.2% | +0.7% |
| Nov 17 | RBC Capital | Maintains | Outperform → Outperform | — | $141.07 | $168.00 | +19.1% | +20.6% | +6.1% | -2.5% | -0.2% | +0.7% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $137.22 | $142.24 | +3.7% | -2.3% | -2.2% | +1.5% | +2.9% | -0.3% |
| Oct 27 | JP Morgan | Maintains | Overweight → Overweight | — | $138.53 | $140.00 | +1.1% | +0.6% | -0.9% | -1.7% | +0.4% | +1.0% |
| Oct 20 | Morgan Stanley | Maintains | Overweight → Overweight | — | $136.06 | $137.18 | +0.8% | -0.9% | +2.0% | +0.7% | -0.2% | +0.3% |
| Sep 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $129.40 | $129.80 | +0.3% | +0.1% | -1.4% | -0.6% | +1.6% | +2.2% |
| Aug 29 | Goldman Sachs | Maintains | Buy → Buy | — | $126.13 | $126.06 | -0.1% | +1.3% | +1.5% | +1.6% | -2.8% | +1.2% |
| Aug 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $124.43 | $124.43 | +0.0% | +1.4% | +1.3% | +1.5% | +1.6% | -2.8% |
| Aug 28 | RBC Capital | Maintains | Outperform → Outperform | — | $124.43 | $124.43 | +0.0% | +1.4% | +1.3% | +1.5% | +1.6% | -2.8% |
| Aug 28 | Truist | Maintains | Buy → Buy | — | $124.43 | $124.43 | +0.0% | +1.4% | +1.3% | +1.5% | +1.6% | -2.8% |
| Aug 28 | Needham | Maintains | Buy → Buy | — | $124.43 | $124.43 | +0.0% | +1.4% | +1.3% | +1.5% | +1.6% | -2.8% |
| Aug 20 | Needham | Maintains | Buy → Buy | — | $119.20 | $119.73 | +0.4% | -0.1% | +1.2% | +2.1% | +1.2% | +0.3% |
| Aug 6 | Morgan Stanley | Maintains | Overweight → Overweight | — | $113.20 | $107.55 | -5.0% | -6.4% | +5.8% | -0.7% | -0.5% | +2.3% |
| Jul 22 | Morgan Stanley | Maintains | Overweight → Overweight | — | $112.65 | $112.17 | -0.4% | +3.3% | +0.9% | +0.6% | +0.2% | -0.7% |
| Jun 11 | Needham | Maintains | Buy → Buy | — | $113.00 | $113.18 | +0.2% | -2.2% | -0.2% | -1.6% | +1.1% | -2.4% |
| Jun 3 | Needham | Maintains | Buy → Buy | — | $108.29 | $108.81 | +0.5% | +1.9% | -0.8% | -0.6% | +2.1% | +0.7% |
| May 7 | Baird | Maintains | Outperform → Outperform | — | $111.17 | $105.51 | -5.1% | -8.8% | -3.0% | -0.6% | +5.9% | -0.6% |
| May 7 | RBC Capital | Maintains | Outperform → Outperform | — | $111.17 | $105.51 | -5.1% | -8.8% | -3.0% | -0.6% | +5.9% | -0.6% |
| May 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $111.17 | $105.51 | -5.1% | -8.8% | -3.0% | -0.6% | +5.9% | -0.6% |
| May 7 | Morgan Stanley | Maintains | Overweight → Overweight | — | $111.17 | $105.51 | -5.1% | -8.8% | -3.0% | -0.6% | +5.9% | -0.6% |
| May 7 | Needham | Maintains | Buy → Buy | — | $111.17 | $105.51 | -5.1% | -8.8% | -3.0% | -0.6% | +5.9% | -0.6% |
| Apr 10 | Needham | Maintains | Buy → Buy | — | $110.12 | $108.04 | -1.9% | -7.3% | -1.5% | +1.2% | +1.1% | -1.3% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $138.81 | $138.19 | -0.4% | -1.0% | -0.4% | -2.0% | +1.4% | +1.4% |
| Mar 7 | UBS | Upgrade | Neutral → Buy | — | $136.45 | $139.18 | +2.0% | +1.7% | -1.0% | -0.4% | -2.0% | +1.4% |
| Mar 6 | Truist | Maintains | Buy → Buy | — | $140.23 | $138.27 | -1.4% | -2.7% | +1.7% | -1.0% | -0.4% | -2.0% |
| Mar 5 | Needham | Maintains | Buy → Buy | — | $138.95 | $139.28 | +0.2% | +0.9% | -2.7% | +1.7% | -1.0% | -0.4% |
| Feb 27 | Barclays | Maintains | Overweight → Overweight | — | $144.17 | $142.51 | -1.2% | -0.6% | +0.2% | -2.3% | -0.9% | +0.9% |
| Feb 26 | JP Morgan | Maintains | Overweight → Overweight | — | $139.67 | $140.50 | +0.6% | +3.2% | -0.6% | +0.2% | -2.3% | -0.9% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $139.67 | $140.50 | +0.6% | +3.2% | -0.6% | +0.2% | -2.3% | -0.9% |
| Feb 26 | Piper Sandler | Maintains | Overweight → Overweight | — | $139.67 | $140.50 | +0.6% | +3.2% | -0.6% | +0.2% | -2.3% | -0.9% |
| Feb 26 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | — | $139.67 | $140.50 | +0.6% | +3.2% | -0.6% | +0.2% | -2.3% | -0.9% |
| Feb 26 | RBC Capital | Maintains | Outperform → Outperform | — | $139.67 | $140.50 | +0.6% | +3.2% | -0.6% | +0.2% | -2.3% | -0.9% |
| Feb 13 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $135.44 | $137.65 | +1.6% | +1.0% | -2.1% | +1.1% | -0.3% | +1.3% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Smith Mark DouglasDir | — | Sell | 1,157 | $230.55 | $267K | 9,680 | -1.00% | — |
| Jun 10, 2026 | Patil Neena MOff | EVP & Chief Legal Officer | Sell | 1,200 | $231.83 | $278K | 51,549 | +0.01% | — |
| Jun 1, 2026 | COZADD BRUCE CDir | — | Sell | 6,000 | $235.12 | $1.4M | 372,682 | +3.95% | +0.19% |
| May 28, 2026 | Patil Neena MOff | EVP & Chief Legal Officer | Sell | 1,192 | $236.97 | $282K | 52,626 | -2.80% | -2.74% |
| May 28, 2026 | Pearce SamanthaOff | EVP, Chief Commercial Officer | Sell | 6,907 | $235.41 | $1.6M | 50,272 | -2.80% | -2.74% |
| May 22, 2026 | Winningham Rick EDir | — | Sell | 2,741 | $241.57 | $662K | 9,567 | -0.92% | +2.13% |
| May 22, 2026 | McSharry Heather AnnDir | — | Sell | 2,000 | $241.00 | $482K | 18,449 | -0.92% | +2.13% |
| May 1, 2026 | COZADD BRUCE CDir | — | Sell | 6,000 | $203.33 | $1.2M | 378,682 | +7.68% | +1.89% |
8-K · 8.01
!! High
AbCellera Biologics Inc. -- 8-K 8.01: Material Event / Announcement
AbCellera partnered with Jazz Pharmaceuticals to develop antibody candidates for gastrointestinal cancers and solid tumors, combining AbCellera's discovery platform with Jazz's development expertise.
Jun 17
8-K
Jazz Pharmaceuticals, Inc. -- 8-K Filing
Jazz Pharmaceuticals achieved record $1.2 billion Q4 revenue with 10% YoY growth, positioning the company favorably for 2026 with planned zanidatamab launch and sustained momentum across key products.
Feb 24
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Portfolio Management Llc | 2,983,242 | $564M | New | Mar 2026 |
| 2 | Capital World Investors | 2,673,376 | $505M | — | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 2,648,333 | $501M | New | Mar 2026 |
| 4 | Fmr Llc | 2,275,762 | $430M | Added | Mar 2026 |
| 5 | Franklin Resources Inc | 1,958,940 | $370M | Added | Mar 2026 |
| 6 | Bank Of New York Mellon Corp | 1,679,371 | $317M | Added | Mar 2026 |
| 7 | Aqr Capital Management Llc | 1,338,458 | $250M | Added | Mar 2026 |
| 8 | Millennium Management | 1,262,511 | $239M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 1,259,444 | $238M | Added | Mar 2026 |
| 10 | Jpmorgan Chase & Co | 1,204,353 | $221M | Added | Mar 2026 |
| 11 | Morgan Stanley | 1,278,358 | $217M | Reduced | Dec 2025 |
| 12 | Bank Of America Corp /de/ | 1,014,800 | $192M | Added | Mar 2026 |
| 13 | Swedbank Ab | 992,108 | $188M | Reduced | Mar 2026 |
| 14 | Bnp Paribas Asset Management Holding S.a. | 885,201 | $167M | Added | Mar 2026 |
| 15 | Renaissance Technologies Llc | 819,374 | $155M | Reduced | Mar 2026 |
| 16 | Boston Trust Walden Corp | 488,661 | $92M | Added | Mar 2026 |
| 17 | Northern Trust Corp | 488,522 | $92M | Added | Mar 2026 |
| 18 | Polaris Capital Management, Llc | 415,366 | $79M | Reduced | Mar 2026 |
| 19 | Alyeska Investment Group, L.p. | 411,015 | $78M | Added | Mar 2026 |
| 20 | Systematic Financial Management Lp | 407,114 | $77M | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$14.11B
Enterprise Value
$15.59B
P/E (TTM)
-38.47x
Forward P/E
9.29x
PEG Ratio
0.18x
P/B
3.17x
P/S
3.21x
P/FCF
10.56x
EV/EBITDA
143.71x
Shares Out
61.0M
Financials (TTM)
Revenue
$4.27B
Net Income
-$356.1M
EBITDA
$108.5M
Free Cash Flow
$1.30B
Op Cash Flow
$1.36B
EPS Basic
$-5.84
EPS Diluted
$-5.84
EPS Forward
$24.19
Gross Margin
88.2%
Op Margin
5.3%
Net Margin
-8.3%
Balance Sheet
Total Assets
$11.66B
Total Liab.
$7.34B
Total Equity
$4.32B
Cash
$2.44B
LT Debt
$4.33B
Book Value/Sh
$70.81
Debt/Equity
1.26x
Current Ratio
1.86
Quick Ratio
1.67
Returns & Growth
ROE
-8.2%
ROA
-3.0%
ROIC
1.2%
Rev Growth YoY
+4.9%
EPS Growth YoY
-164.5%
Price Returns
2W
+2.4%
1M
+16.5%
3M
+24.5%
6M
+34.0%
12M
+118.8%
Technicals
52W High
$243.32
52W Low
$105.00
50d MA
$220.26
200d MA
$175.05
RSI (14)
39.00
ATR (14)
$6.87
Beta
0.23
Avg Volume
934K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$216.14
High
$235.00
Low
$188.00
Median
$225.00
Data updated apr 25, 2026 4:40pm
· Source: financialmodelingprep.com